Liver Transplantation Program in Uruguay: analysis and results.
DOI:
https://doi.org/10.35954/SM2011.30.1.3Keywords:
Liver Cirrhosis; Hepatopathies; Hepato-carcinoma; Liver Transplantation.Abstract
Liver transplantation is the only option for the treatment of advanced stages of chronic liver diseases, fulminant hepatitis and selected cases of tumors. Indications have increased and contraindications have been reduced, reporting 90% and 80% survival at one year and 5 years respectively.
OBJECTIVE: To describe the activity carried out in the re-initiation of the liver transplant program in Uruguay.
MATERIALS AND METHODS: A retrospective descriptive study of patients transplanted between July 2009 and July 2010 in the Oriental Republic of Uruguay was carried out.
RESULTS: 13 patients were transplanted, all with chronic hepatopathies where 4 hepatocarcinomas were inserted, 3 were re-operated. Twelve patients were extubated before the first 24 hours. The average length of stay was 2.5 and 14 days in CTI and ward respectively. The most frequent immediate postoperative complications were pulmonary edema and renal insufficiency. Initial immunosuppression was performed with corticosteroids, calcineurin inhibitors and mycophenolate mofetil. Five rejections were recorded. Two patients died.
CONCLUSIONS: The results in terms of morbidity and mortality are very satisfactory, adequate for a program that is starting.
Downloads
Metrics
References
(1) STARZL TE, MARCHIORO TL, VONKAULLA KN, HERMANN G, BRITTAIN RS, WADDELL WR. Homotransplantation of the Liver in Humans. Surg Gynecol Obstet 1963; 117:659-76.
(2) CALNE RY, WILLIAMS R. Orthotopic liver transplantation: the first 60 patients. Br Med J 1977; 1:471-6.
(3) NATIONAL INSTITUTES OF HEALTH. Consensus development conference statement: liver transplantation. Hepatology 1984; 4(1 suppl):107S- 110S.
(4) CASTELLI J, PROSPER E. Análisis descriptivo del postoperatorio inmediato de los trasplantes hepáticos ortotópicos en Uruguay. Pac Crítico 2001; 14:105- 6.
(5) HARGUINDEGUY M, LEITES A, ETTLIN A. Resultados de una unidad de referencia. Servicio de Enfermedades Hepáticas HCFFAA. 2007; Presentado en el Congreso Uruguayo de Cirugía.
(6) BERENGUER J, PARRILLA P. Trasplante Hepático. 2ª. ed. Murcia - España : Elsevier, 2007.
(7) HEPP J, ZAPATA R, BUCKEL E. Trasplante hepático en Chile: Aspectos generales, indicaciones y contraindicaciones. Rev. Méd. Chile 2008; 136:793-804.
(8) CARITHERS RL, JR. Liver transplantation. American Association for the Study of Liver Diseases. Liver Transpl 2000; 6: 122-35.
(9) DEVLIN J, O’GRADY J. Indications for referral and assessment in adult liver transplantation: a. Gut 1999; 45(6 suppl):VI1-VI22 .
(10) CONSENSUS CONFERENCE. Indications for Liver Transplantation, January 19 and 20. Liver Transpl 2006; 12:998-1011.
(11) MAZZAFERRO V, REGALIA E, DOCI R, ANDREOLA S, PULVIRENTI A, BOZZETTI F, MONTALTO F, AMMATUNA M, MORABITO A, GENNARI L. Liver transplantation for the treatment of small hepatocellular carcinomas in. N Engl J Med 1996; 334: 693-9.
(12) MALINCHOC M, KAMATH PS, GORDON FD, PEINE CJ, RANK J, TER BORG PC. A model to predict poor survival in patients undergoing transjugular intrahepatic. Hepatology 2000; 31:864-71.
(13) KAMATH PS, WIESNER RH, MALINCHOC M, KREMERS W, THERNEAU TM, KOSBERG CL, D’AMICO G, DICKSON ER, KIM WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-70.
(14) WIESNER R, EDWARDS E, FREEMAN R, HARPER A, KIM R, KAMATH P, KREMERS W, LAKE J, HOWARD T, MERION RM, WOLFE RA, KROM R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91-6.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
